Skip to main content

Table 1 Patient demographics and baseline disease characteristics (N = 30 patients)

From: Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

Variable

No. of patients (%)

Age (years; Median (range)

61 (37–76)

Cutaneous primary

21 (70)

Unknown primary

8 (27)

Mucosal

1 (3)

Gender

 Female

12 (40)

 Male

18 (60)

Performance status

 0

16 (53)

 1

14 (47)

Recurrent disease after prior surgery

15 (50)

Presence of in-transit metastases

16 (53)

Prior adjuvant HDI

5 (17)

Estimated risk Stage

 IIIB

3 (10)

 IIIC

25 (83)

 IV (Not eligible)

2 (7)